Details

Autor(en) / Beteiligte

• Keir, Lindsay S
• Firth, Rachel
• Aponik, Lyndsey
• Feitelberg, Daniel
• Sakimoto, Susumu
• Aguilar, Edith
• Welsh, Gavin I
• Richards, Anna
• Usui, Yoshihiko
• Satchell, Simon C
• Kuzmuk, Valeryia
• Coward, Richard J
• Goult, Jonathan
• Bull, Katherine R
• Sharma, Ruchi
• Bharti, Kapil
• Westenskow, Peter D
• Michael, Iacovos P
• Saleem, Moin A
• Friedlander, Martin

Titel

VEGF regulates local inhibitory complement proteins in the eye and kidney

Ist Teil von

• The Journal of clinical investigation, 2017-01, Vol.127 (1), p.199-214

Ort / Verlag

United States: American Society for Clinical Investigation

Erscheinungsjahr

2017

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Outer retinal and renal glomerular functions rely on specialized vasculature maintained by VEGF that is produced by neighboring epithelial cells, the retinal pigment epithelium (RPE) and podocytes, respectively. Dysregulation of RPE- and podocyte-derived VEGF is associated with neovascularization in wet age-related macular degeneration (ARMD), choriocapillaris degeneration, and glomerular thrombotic microangiopathy (TMA). Since complement activation and genetic variants in inhibitory complement factor H (CFH) are also features of both ARMD and TMA, we hypothesized that VEGF and CFH interact. Here, we demonstrated that VEGF inhibition decreases local CFH and other complement regulators in the eye and kidney through reduced VEGFR2/PKC-α/CREB signaling. Patient podocytes and RPE cells carrying disease-associated CFH genetic variants had more alternative complement pathway deposits than controls. These deposits were increased by VEGF antagonism, a common wet ARMD treatment, suggesting that VEGF inhibition could reduce cellular complement regulatory capacity. VEGF antagonism also increased markers of endothelial cell activation, which was partially reduced by genetic complement inhibition. Together, these results suggest that VEGF protects the retinal and glomerular microvasculature, not only through VEGFR2-mediated vasculotrophism, but also through modulation of local complement proteins that could protect against complement-mediated damage. Though further study is warranted, these findings could be relevant for patients receiving VEGF antagonists.